What is claimed is:

1. A compound~~, including pharmaceutically acceptable salts thereof,~~ which is selected from the group consisting of:

a compound of formula I



Formula I ;

a compound of formula II



Formula II ;

a compound of formula III



Formula III ;

and a compound of formula IV



Formula IV ;

wherein R_1 is isopropenyl or isopropyl;

J and E are independently –H or $–CH_3$, and E is absent when the double bond is present;

X is selected from the group of C_{4-8} cycloalkyl, C_{4-8} cycloalkenyl, C_{4-9} spirocycloalkyl, C_{4-9} spirocycloalkenyl, C_{4-8} oxacycloalkyl, C_{4-8} dioxacycloalkyl, C_{6-8} oxacycloalkenyl, C_{6-8} dioxacycloalkenyl, C_6 cyclodialkenyl, C_6 oxacyclodialkenyl, C_{6-9} oxaspirocycloalkyl and C_{6-9} oxaspirocycloalkenyl ring, wherein X is substituted with A, wherein A is at least one member selected from the group of -H, -halo, -hydroxyl, -C_{1-6} alkyl, -C_{1-6} alkoxy, -C_{1-6} alkyl-Q, -alkylsubstituted C_{1-6} alkyl-Q, -CN, $-CF_2Q$, $-NR_8R_9$, $-COOR_2$ and $-CONR_2R_2$;
X is ~~can~~ also ~~be~~ selected from the group of:



;

wherein Q is selected from the group of aryl, heteroaryl, substituted heteroaryl, $-OR_2$, $-COOR_3$, $-NR_2R_2$, $-SO_2R_7$, $-CONHSO_2R_3$, and $-CONHSO_2NR_2R_2$;

R_2 is -H, -C_{1-6} alkyl, -alkylsubstituted C_{1-6} alkyl or-arylsubstituted C_{1-6} alkyl;

Y is selected from the group of $–COOR_2$, $-C(O)NR_2SO_2R_3$, $- C(O)NHSO_2NR_2R_2$, $-NR_2SO_2R_2$, $-SO_2NR_2R_2$, -C_{3-6} cycloalkyl-$COOR_2$, -C_{2-6} alkenyl-$COOR_2$, -C_{2-6} alkynyl-$COOR_2$, -C_{1-6} alkyl-$COOR_2$, -alkylsubstituted C_{1-6} alkyl, $-COOR_2$, CF_2-$COOR_2$, $-NHC(O)(CH_2)_n$-$COOR_2$, $-SO_2NR_2C(O)R_2$, tetrazole, and -CONHOH, wherein n=1-6;

R_7 is selected from the group of -C_{1-6} alkyl, -C_{1-6} substituted alkyl, -C_{3-6} cycloalkyl, -CF_3, aryl, and heteroaryl;

R_8 and R_9 are independently selected from the group of -H, -C_{1-6} alkyl, -C_{1-6} substituted alkyl, aryl, heteroaryl, substituted aryl, substituted heteroaryl, -C_{1-6} alkyl-Q_2, and -$COOR_3$,

and R_8 and R_9 <u>are</u> ~~can~~ also ~~be~~ independently selected from the group of



and


,

or R_8 and R_9 are taken together with the adjacent N to form a cycle selected from the group of:



,


,


,


,


,



,


,


,


,


,



,


,


,


,


and


,

with the proviso that only one of R_8 or R_9 <u>is</u> ~~can be~~ -$COOR_3$;

R_{10} and R_{11} are independently selected from the group of -H, -C_{1-6} alkyl, -C_{1-6} substituted alkyl and -C_{3-6} cycloalkyl,

or R_{10} and R_{11} are taken together with the adjacent N to form <u>the</u> ~~a~~ cycle ~~such as~~



;

R_{18} is selected from the group of $-COOR_2$ and $-C_{1-6}$ alkyl-$COOR_2$;

R_{19} is selected from the group of -H, $-C_{1-6}$ alkyl, $-C_{1-6}$ alkyl-Q_4, $-COR_3$, $-COOR_3$,
wherein Q_4 is selected from the group of $-NR_2R_2$ and $-OR_2$;

R_{20} and R_{21} are independently selected from the group of -H, $-C_{1-6}$ alkyl, $-C_{1-6}$ substituted alkyl, $-C_{1-6}$ substituted alkyl-OR_2, and $-COR_3$,
or R_{20} and R_{21} are taken together with the adjacent N to form a cycle selected from the group of



with the proviso that only one of R_{20} or R_{21} is ~~can be~~ $-COR_3$;

R_{22} and R_{23} are independently selected from the group of H, $-C_{1-6}$ alkyl, $-C_{1-6}$ substituted alkyl, and $-C_{1-6}$ cycloalkyl,
or R_{22} and R_{23} are taken together with the adjacent N to form a cycle selected from the group of



R_{24} and R_{25} are independently from the group of H, $-C_{1-6}$ alkyl, $-C_{1-6}$ substituted alkyl, $-C_{1-6}$ alkyl-Q_5, $-C_{1-6}$ cycloalkyl, aryl, substituted aryl, heteroaryl, and substituted heteroaryl,
and Q_5 is selected from the group of halogen and SO_2R_3;
and pharmaceutically acceptable salts thereof.

2. The compound as claimed in claim 1, wherein said compound is a compound of ~~has the~~ Formula I.

3. The compound as claimed in claim 1, wherein said compound is a compound of ~~has the~~ Formula II.

4. The compound as claimed in claim 1, wherein said compound is a compound of ~~has the~~ Formula III.

5. The compound as claimed in claim 2, wherein R_1 is isopropenyl.

6. The compound as claimed in claim 5, wherein X is selected from the group of C_{4-8} cycloalkenyl, C_{4-9} spirocycloalkyl, and C_{4-9} spirocycloalkenyl.

7. The compound as claimed in claim 6, wherein Y is $-COOR_2$.

8. The compound as claimed in claim 7, wherein Y is –COOH.

9. The compound as claimed in claim 6, wherein A is –H.

10. The compound as claimed in claim 2, wherein said compound is a compound with the ~~has the~~ following general structure selected from the group of:



and



11. A compound~~, including pharmaceutically acceptable salts thereof,~~ which is selected from the group consisting of:



,



,



,



,



,



, and



and pharmaceutically acceptable salts thereof.

12. A pharmaceutical composition which comprises an HIV ameliorating ~~antiviral effective~~ amount of one or more of the compounds as claimed in claim 1, together with one or more pharmaceutically acceptable carriers, excipients or diluents.

13. A pharmaceutical composition which comprises an HIV ameliorating ~~antiviral effective~~ amount of one or more of the compounds as claimed in claim 10, together with one or more pharmaceutically acceptable carriers, excipients or diluents.

14. A pharmaceutical composition which comprises an HIV ameliorating ~~antiviral effective~~ amount of one or more of the compounds as claimed in claim 11, together with one or more pharmaceutically acceptable carriers, excipients or diluents.

15. The pharmaceutical composition of claim 12, useful for treating infection by HIV, which additionally comprises an HIV ameliorating ~~antiviral effective~~ amount of an AIDS treatment agent selected from the group consisting of: (a) an AIDS antiviral agent; (b) an anti-infective agent; (c) an immunomodulator; and (d) another HIV entry inhibitor.

~~16. A method for treating a mammal infected with the HIV virus comprising administering to said mammal an antiviral effective amount of a compound as claimed in claim 1, and one or more pharmaceutically acceptable carriers, excipients or diluents.~~

~~17~~16. The compound as claimed in claim 1, wherein W is absent.

~~18~~17. The compound as claimed in claim 1, wherein said compound is a compound of ~~has the~~ Formula IV.

~~19~~18. The intermediate compound which is selected from the group of



;



;



;



;



; and